Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
6.66
-0.14 (-2.06%)
Aug 13, 2025, 4:00 PM - Market closed
Nutriband Revenue
Nutriband had revenue of $667.43K in the quarter ending April 30, 2025, with 63.37% growth. This brings the company's revenue in the last twelve months to $2.40M, up 18.92% year-over-year. In the fiscal year ending January 31, 2025, Nutriband had annual revenue of $2.14M with 2.60% growth.
Revenue (ttm)
$2.40M
Revenue Growth
+18.92%
P/S Ratio
30.82
Revenue / Employee
$184,495
Employees
13
Market Cap
74.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jan 31, 2025 | 2.14M | 54.22K | 2.60% |
Jan 31, 2024 | 2.09M | 5.71K | 0.27% |
Jan 31, 2023 | 2.08M | 657.46K | 46.23% |
Jan 31, 2022 | 1.42M | 478.45K | 50.70% |
Jan 31, 2021 | 943.70K | 573.06K | 154.61% |
Jan 31, 2020 | Pro | Pro | Pro |
Jan 31, 2019 | Pro | Pro | Pro |
Jan 31, 2018 | Pro | Pro | Pro |
Jan 31, 2017 | Pro | Pro | Pro |
Jan 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NTRB News
- 3 days ago - Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election - GlobeNewsWire
- 6 days ago - FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 27 days ago - Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval - GlobeNewsWire
- 6 weeks ago - Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval - GlobeNewsWire
- 6 weeks ago - Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index - GlobeNewsWire
- 2 months ago - Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology - GlobeNewsWire
- 3 months ago - Nutriband CEO Publishes Letter to Shareholders - GlobeNewsWire
- 4 months ago - Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology - GlobeNewsWire